Life Sciences Consulting Case Interview: Pharma, Biotech, and MedTech Cases (2026)

Life sciences consulting case interviews require industry-specific knowledge that generic consulting frameworks cannot substitute: FDA regulatory timelines, clinical trial economics, payer dynamics, and drug pricing mechanics. Candidates who treat a drug launch case like a market entry case (using Porter's Five Forces or a generic go/no-go tree) fail because they miss the variables that actually determine commercial success in pharma: formulary access, PBM rebate negotiation, HEOR evidence requirements, and patent cliff timing.

What life sciences cases test

• Industry vocabulary matters: FDA phases, NDA/BLA, PBMs, HEOR, formulary tiers, rNPV, patent cliff, and LOE.
• The most reusable structure is market assessment, pricing strategy, payer access, and commercial model.
• ZS leans commercial analytics and market access; the L.E.K. / LEK case interview guide is the better fit for life sciences strategy and diligence; Huron leans healthcare operations and life sciences commercialization.
• Simon-Kucher is the pricing-heavy path inside pharma cases, especially drug pricing and value communication.
• Generic consulting frameworks are only a starting point. Adapt them to payer, provider, patient, and regulator constraints before you recommend.

What Makes Life Sciences Cases Unique

The payer/provider/patient triangle is the central framework that all life sciences consulting cases revolve around:

• Patient: Who has the disease? How are they diagnosed? Are they treatment-naive or pre-treated?
• Provider: Which physicians prescribe? What drives their prescribing decisions (efficacy data, safety profile, peer influence, KOL opinion)?
• Payer: Will insurance cover the drug? At what tier? What prior authorization requirements will limit patient access?

Layered over this triangle are three additional constraints that standard consulting cases do not include:

1. FDA regulatory pathway: Is this a New Drug Application (NDA) for a small molecule or a Biologics License Application (BLA) for a biologic? What clinical evidence is required for approval? What label restrictions might limit the indicated population?
2. Patent and exclusivity timelines: When does the molecule lose market exclusivity? Is a biosimilar competitor likely within the commercial forecast window?
3. Health economics and outcomes evidence: Does the drug's value proposition hold up to a cost-effectiveness analysis? What HEOR data will payers require before granting favorable formulary access?

Failing to account for any of these three factors will immediately signal to your interviewer that you lack the industry foundation the firm expects.

Key Life Sciences Case Types

1. Drug Launch Strategy

The most common life sciences case type. A pharma company has received FDA approval for a new drug and needs a go-to-market plan. The answer requires a 4-part structure (detailed in the worked example below): market assessment, pricing strategy, payer/market access strategy, and commercial model.

Firms that use this type: L.E.K. Consulting, McKinsey Life Sciences, BCG Biopharma, Simon-Kucher

2. Portfolio Prioritization and Pipeline Asset Allocation

A pharma or biotech company has multiple pipeline assets at various stages and limited R&D budget. Which assets should they fund? This requires risk-adjusted NPV (rNPV) modeling (applying stage-specific probability of success to projected cash flows before discounting) alongside strategic criteria like competitive differentiation and unmet need.

Firms that use this type: L.E.K. Consulting, Bain, McKinsey Life Sciences

3. Market Access and Payer Strategy

A drug has been approved but is facing formulary exclusion or unfavorable tier placement by major PBMs (Express Scripts, CVS Caremark, OptumRx). How does the company improve access? This requires understanding rebate economics, HEOR evidence generation, and patient assistance program design.

Firms that use this type: ZS Associates, Huron Life Sciences, IQVIA

4. Pharma/Biotech M&A and Due Diligence

A large pharma company is evaluating acquiring a mid-size biotech with a Phase III asset. Is it worth the purchase price? This requires rNPV modeling, competitive landscape analysis, commercial potential sizing, and integration risk assessment.

Firms that use this type: L.E.K. Consulting, BCG Biopharma, McKinsey

5. Medical Device Market Sizing

How large is the addressable market for a new surgical robot? A continuous glucose monitor? This is a medical device version of the standard market sizing framework but requires knowledge of procedure volumes, hospital purchasing dynamics, and reimbursement codes (CPT codes, DRG groupings).

Firms that use this type: L.E.K. Consulting, Huron Life Sciences, Deloitte

Firms That Specialize in Life Sciences Consulting

L.E.K.'s life science case interviews often include market sizing and strategic assessment, such as whether a pharma company should enter a new disease area. ZS Associates cases are candidate-led and heavily weighted toward market access, pricing, and salesforce effectiveness in healthcare and pharma contexts. Huron cases tend to emphasize healthcare operations, revenue cycle, clinical strategy, and commercialization execution.

Essential Life Sciences Terminology

Before your interview, you must know these terms well enough to use them naturally, not just define them when asked.

Understanding PBM mechanics and formulary dynamics is table stakes for any market access or drug launch case. PBMs sit between manufacturers and payers, negotiating rebates from manufacturers in exchange for formulary placement. A drug excluded from a major formulary can lose meaningful access even if physicians like the clinical profile.

Patent cliffs are equally critical: branded drugs can lose revenue quickly after generic or biosimilar entry, especially when multiple competitors enter and substitution is easy. This makes life-cycle management (reformulations, new indications, combination products) a recurring case topic.

Worked Example: Oncology Drug Launch Strategy

Prompt: "Your client, a mid-size biotech, received FDA approval 6 months ago for a new PD-L1 inhibitor in second-line non-small cell lung cancer (NSCLC). Sales are tracking 40% below forecast. What's going wrong, and what should they do?"

Step 1: Clarify the situation

• What is the target patient population size, and how many patients have been identified and treated?
• What is the current formulary status with the three largest PBMs?
• How does the drug compare to Keytruda (pembrolizumab) and Opdivo (nivolumab) on efficacy, safety, and price?
• Is there a companion diagnostic required (i.e., PD-L1 expression test before prescribing)?

Step 2: Market assessment

Step 3: Pricing and market access diagnosis

If sales are 40% below forecast, the most common culprits in a biotech launch are:

1. Formulary exclusion or unfavorable tier placement: a major PBM excluded the drug or placed it on Tier 3, making patient co-pays prohibitive
2. Prior authorization burden: payers require extensive documentation that slows time-to-treatment and discourages oncologist use
3. HEOR evidence gap: the drug lacks comparative effectiveness data vs. Keytruda, so payers are not granting preferred access despite similar clinical outcomes

Step 4: Commercial model gaps

• Is the salesforce appropriately sized for oncology (smaller, specialist-focused)?
• Are medical science liaisons (MSLs) engaging with the right academic medical centers?
• Is there a robust patient services program helping patients navigate prior authorization?

Step 5: Recommendations

Immediate (0–3 months): Negotiate with the two excluded PBMs using HEOR data and WAC-to-net rebate adjustments to achieve Tier 2 placement. Implement a PAP (patient assistance program) to remove cost as a barrier for uninsured patients.

Medium-term (3–12 months): Commission a real-world evidence study comparing outcomes for patients on the new drug vs. standard of care, using IQVIA or Symphony Health claims data. Use this HEOR evidence in payer negotiations and formulary committee submissions.

Long-term: Pursue label expansion to first-line NSCLC with a biomarker-selected subpopulation. This dramatically expands TAM and reduces competitive intensity vs. Keytruda.

Quantification: If achieving Tier 2 placement with the two largest PBMs captures an incremental 15% of the addressable patient population at an average net price of $150,000/year, this translates to approximately $225M in additional annual revenue on a patient base of 10,000 eligible patients.

Common Mistakes in Life Sciences Cases

1. Treating the FDA process as a black box. Saying "the drug gets approved and then you launch" misses 2–4 years of commercial preparation that happens during Phase III. Labels, pricing strategies, and payer negotiations begin during clinical development.

2. Ignoring payer dynamics. Assuming that physician recommendation drives prescribing without accounting for formulary access and prior authorization is a critical gap. In the US, payer access determines whether patients can actually receive a drug.

3. Using generic market sizing without understanding patient identification. A pharma market sizing must account for diagnosed vs. undiagnosed patients, treatment-eligible vs. non-eligible subsets, and patient identification rates. Not all patients in the "addressable" population are actually treated.

4. Conflating WAC and net price. The list price (WAC) of a drug is meaningless in isolation; net price after PBM rebates is what the manufacturer actually receives. In some therapeutic areas, rebates of 40–60% are standard.

5. Missing the biosimilar/generic timeline. If the drug being launched is a biologic with LOE in 5 years, that changes the commercial forecast horizon and NPV calculation fundamentally.

30-Day Prep Plan for Life Sciences Candidates

Week 1: Industry foundation

• Read Hacking the Case Interview's life sciences guide end-to-end
• Study FDA regulatory pathways: IND → Phase I → Phase II → Phase III → NDA/BLA → approval
• Learn PBM mechanics, formulary tiers, and prior authorization process
• Review pharma case interview examples and healthcare case interview prep

Week 2: Core frameworks

• Practice the 4-part drug launch structure (market, pricing, access, commercial)
• Learn rNPV mechanics for pipeline/M&A cases
• Practice medical device market sizing with procedure volume data
• Review the market sizing framework and profitability framework for adaptation to life sciences

Week 3: Case practice with terminology

• Solve 2 drug launch cases using the full 4-part framework, timing each section
• Practice 2 market access cases focused on PBM negotiation and formulary positioning
• Complete 1 M&A/due diligence case with rNPV framing
• Run one Road to Offer case rep and debrief whether your recommendation connected clinical evidence, payer access, and commercial execution
• Review the ZS Associates case interview guide and L.E.K.-specific case format notes

Week 4: Mock interviews and firm-specific prep

• Run 2 full mock interviews with a partner using case interview practice partner guide
• Review McKinsey's public GlobaPharm case (available on McKinsey's careers page), an excellent life sciences case with HEOR and market access elements
• Prepare 3 behavioral stories specific to life sciences context: managing complexity, working across payer/provider/patient stakeholders, data-driven decisions
• Study Huron consulting case interview guide for healthcare operations case types

Checklist

Execution checklist

• Can explain FDA phases I/II/III and NDA/BLA process

  Life sciences interviewers assume basic regulatory knowledge; gaps immediately signal lack of industry foundation

• Understand PBM mechanics and formulary tier impact on patient access

  Payer dynamics are the central variable in every drug launch and market access case

• Practiced 4-part drug launch framework with quantified examples

  This structure appears in the majority of life sciences launch cases across L.E.K., ZS, and McKinsey

• Know key firms: L.E.K., ZS Associates, Huron, IQVIA, Simon-Kucher

  Each firm has a different focus within life sciences; knowing the firm's niche shapes your case approach

• Can explain rNPV vs. standard NPV and when to use each

  Pipeline and M&A cases always require rNPV framing; standard DCF misses development risk

• Prepared HEOR definition and why payers require this evidence

  HEOR is a recurring concept in market access cases and interviewers will probe your understanding

Related Guides

• Pharma Case Interview Guide
• Healthcare Case Interview Guide
• Pricing Strategy Cases: drug pricing, payer negotiations, and value-based contracts are core to life sciences commercial strategy
• PE Due Diligence Framework: the diligence layer for pipeline and asset M&A
• Market Sizing Framework
• Unit Economics Framework

Sources (reviewed June 10, 2026)

1. Life Sciences Consulting Case Interview: Complete Guide (Hacking the Case Interview)
2. ZS Case Interview: The Complete Prep Guide 2026 (Hacking the Case Interview)
3. L.E.K. Consulting Life Science Associate Interview Questions (Glassdoor)
4. Pharma Case Interview Practice (ZS Associates)
5. PBMs, Formularies, and Rebates: What Investors Should Know (DrugPatentWatch)
6. Patent Cliff Playbook: Formulary Management in the Age of Generic Entry (DrugPatentWatch)
7. Valuing Pharmaceutical Assets: When to Use NPV vs rNPV (Alacrita)
8. Pharma Case Interview Example (Management Consulted)
9. Managing the Pharmacy Benefit: The Formulary System (PMC)